NCT00551447CompletedPhase 3
A Comparison of Treatment With Ezetimibe (SCH 58235) and Simvastatin Coadministration Versus Simvastatin in Attaining the National Cholesterol Education Program (NCEP) Adult Treatment Panel (ATP) III Coronary Heart Disease (CHD) or CHD Risk Equivalent Strata Low-Density Lipoprotein Cholesterol (LDL-c)
Conditions
Drugs
Trial Snapshot
- Phase
- Phase 3
- Status
- Completed
- Sponsor
- Organon and Co
- Enrollment
- 616
- Primary Endpoint
- LDL-C measurement (target goal = <100 mg/dL)
Study Overview
Brief Summary
This purpose of this study is to determine if the administration of ezetimibe and simvastatin together is more effective than simvastatin alone in lowering LDL-C levels to a goal of <100 mg/dL in patients at risk for Heart Disease.
Study Design
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Parallel
- Primary Purpose
- Treatment
- Masking
- Double (Participant, Investigator)
Eligibility Criteria
- Ages
- 18 Years to 80 Years (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Men and women aged 18 to 80 at risk for Heart Disease who have LDL-C levels greater than or equal to 130 mg/dL and triglyceride level less than or equal to 350 mg/dL
- •Patients must be able to maintain the National Cholesterol Education Program diet throughout the course of the study
Exclusion Criteria
- •Patients are excluded from the study if their weight is less than 50% of ideal body weight, if they are pregnant or lactating, have congestive heart failure, uncontrolled heart rhythm problems or a recent heart attack, coronary artery bypass surgery, or angioplasty. Additionally, patients with poorly controlled Type 1 or 2 diabetes mellitus, kidney disease, uncontrolled endocrine or metabolic disease, are known HIV positive, and uncontrolled high blood pressure
Outcomes
Primary Outcomes
LDL-C measurement (target goal = <100 mg/dL)
Time Frame: 27 Weeks
Secondary Outcomes
- Well tolerated in patients(27 Weeks)
Investigators
Similar Trials
Completed
Phase 3
Effect of Ezetimibe Plus Simvastatin Versus Simvastatin Alone on Atherosclerosis in the Carotid Artery (ENHANCE)(P02578)Hyperlipoproteinemia Type IIAtherosclerosisHypercholesterolemiaNCT00552097Organon and Co720
Terminated
Phase 3
Effect of Ezetimibe Plus Simvastatin on Flow-Mediated Brachial Artery Vasoactivity in Subjects With Primary Hypercholesterolemia (Study P03336)AtherosclerosisHypercholesterolemiaNCT00651391Organon and Co28
Completed
Phase 4
The PostprAndial eNdothelial Function After Combination of Ezetimibe and simvAstatin StudyMetabolic SyndromeNCT00817843dr.Frank L.J. Visseren100
Completed
Phase 4
Ezetimibe Plus Simvastatin Versus Simvastatin in Untreated Subjects With High Cholesterol (P03435)HypercholesterolaemiaAtherosclerosisNCT00653835Organon and Co153
Completed
Phase 4
Ezetimibe and Statins on Postprandial Lipemia in Type 2 DiabetesPostprandial LipemiaType 2 DiabetesNCT00699023Federico II University13